Augmedix
Real-time medical scribing now folded into Commure's AI suite
Overview
Augmedix turns clinician-patient conversations into structured EHR notes, either fully automated or via live remote scribes. One of the earliest ambient-scribing companies, it was acquired by Commure for $139M in 2024 and now runs as a subsidiary alongside Athelas.
What you can produce with Augmedix
- Real-time ambient documentation during patient visits
- Augmedix Live: human documentation specialist plus AI, via secure messaging
- Structured EHR note generation
- Reported 14.8-16.1% hourly productivity increase for clinicians
- Deployment for health systems, hospitals and clinics
ASEAN Perspective
Augmedix in Southeast Asia
ASEAN-region availability and pricing notes coming soon. Drop the editorial team a note via /contact/ if you can supply local context (Singapore/Malaysia/Indonesia/Thailand/Vietnam).
Augmedix predates the current ambient-scribe boom — it was doing live remote medical scribing years before Abridge, Nabla and the rest turned it into a crowded category. That history shows in its "Augmedix Live" option: a human documentation specialist paired with the AI via secure messaging, not a fully automated pipeline. Useful for specialties where clinicians don't fully trust unsupervised AI notes yet. Getting absorbed into Commure alongside Athelas in 2024 for $139M gives it institutional backing it lacked as a standalone public company, but its roadmap now serves Commure's broader ambition rather than running independently.
G2 users rate it 4.1/5 and cite real productivity gains — vendor figures claim 14.8-16.1% higher hourly throughput in primary and specialty care. It's sold to health systems and clinics, not individual doctors, with sales-gated pricing and no public API. Want a human-in-the-loop scribe and don't mind the Commure ecosystem, it's credible; want the newest AI-native architecture, competitors built after 2023 are a cleaner story.
What people say
Commure and Athelas announced the deal to acquire Augmedix in mid-2024 for $139M, with Augmedix shareholders receiving $2.35 in cash per share; the transaction closed and Augmedix stock was delisted from Nasdaq by early October 2024. The stated goal was building "one of the largest, most comprehensive AI software suites in healthcare," with the combined companies targeting over 3 million AI-assisted physician appointments.
Augmedix carries a 4.1/5 rating on G2 across a modest review base (16 listed on the G2 seller page). Reviewers — largely clinicians — consistently cite time savings and reduced after-hours charting as the core value, with some describing being able to move faster between patients because documentation is handled in parallel rather than after the visit. A few reviews flag inconsistency in scribe quality as a recurring friction point, which tracks with the human-in-the-loop model: quality depends partly on which documentation specialist is assigned, not just the AI.
Vendor-published productivity figures claim a 14.8% increase in hourly productivity in primary care and 16.1% in specialty care settings, attributed to reduced time-per-note. These are Augmedix's own numbers rather than independently audited.
Since the Commure acquisition, Augmedix's public-facing product and roadmap increasingly overlaps with Athelas Ambient AI and the broader "Commure Ambient AI" branding used in KLAS reporting, so distinguishing the two as separate products going forward is getting harder — worth flagging to anyone evaluating them as distinct options rather than variants of the same parent offering.
Before the acquisition, Augmedix operated as a publicly traded company (Nasdaq: AUGX) for several years, giving it a longer paper trail of audited financials and disclosed customer metrics than most ambient-scribe startups, which tend to be venture-backed and private with figures that come only from press releases. That history is part of why health systems that were early ambient-documentation adopters often have Augmedix, rather than a newer entrant, as their incumbent vendor — switching costs and existing EHR workflow integration favor the company that got there first, even against flashier recent competitors.
Summary of public user & expert reviews, compiled by RECATOOLS.
About this listing
This entry was compiled from publicly available data including Augmedix's official website, press releases, documentation, and reputable third-party publications. RECATOOLS is not affiliated with Augmedix unless explicitly stated.
Third-party AI tools update their pricing, features, availability, and policies frequently. Information here may be outdated by the time you read this — we make reasonable efforts to keep listings current, but cannot guarantee absolute accuracy.
For the latest details, please refer to Augmedix directly →
Spotted something out of date? Suggest an update →
Augmedix in the news
Alternatives to Augmedix
More in Healthcare
